MCID: AGN002
MIFTS: 55

Agnosia

Categories: Eye diseases, Mental diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Agnosia

MalaCards integrated aliases for Agnosia:

Name: Agnosia 12 52 53 43 15 17 71 32
Primary Visual Agnosia 52 71
Apraxias 43 71
Monomodal Visual Amnesia 52
Dyspraxia Syndrome 12
Visual Amnesia 52
Dyspraxia 12
Alexia 71

Classifications:



External Ids:

Disease Ontology 12 DOID:4090
NCIt 49 C84542
SNOMED-CT 67 42341009 68345001
ICD10 32 R48.1 R48.2
UMLS 71 C0001816 C0002018 C0003635 more

Summaries for Agnosia

NIH Rare Diseases : 52 Agnosia is characterized by an inability to recognize and identify objects and/or persons. Symptoms may vary, according to the area of the brain that is affected. It can be limited to one sensory modality such as vision or hearing; for example, a person may have difficulty in recognizing an object as a cup or identifying a sound as a cough. Agnosia can result from strokes, traumatic brain injury, dementia , a tumor , developmental disorders, overexposure to environmental toxins (e.g., carbon monoxide poisoning), or other neurological conditions. Visual agnosia may also occur in association with other underlying disorders. People with agnosia may retain their cognitive abilities in other areas. Treatment of primary agnosia is symptomatic and supportive; when it is caused by an underlying disorder, treatment of the disorder may reduce symptoms and help prevent further brain damage.

MalaCards based summary : Agnosia, also known as primary visual agnosia, is related to pain agnosia and peripheral nervous system disease, and has symptoms including seizures, fever and dyspnea. An important gene associated with Agnosia is TYROBP (Transmembrane Immune Signaling Adaptor TYROBP), and among its related pathways/superpathways are Signaling by GPCR and Peptide ligand-binding receptors. The drugs Nalbuphine and tannic acid have been mentioned in the context of this disorder. Affiliated tissues include brain, parietal lobe and cortex, and related phenotypes are behavior/neurological and homeostasis/metabolism

Disease Ontology : 12 A communication disorder that is a loss of ability to recognize objects, persons, sounds, shapes, or smells while the specific sense is not defective nor is there any significant memory loss.

NINDS : 53 Agnosia is a rare disorder characterized by an inability to recognize and identify objects or persons. People with agnosia may have difficulty recognizing the geometric features of an object or face or may be able to perceive the geometric features but not know what the object is used for or whether a face is familiar or not. Agnosia can be limited to one sensory modality such as vision or hearing. For example, a person may have difficulty in recognizing an object as a cup or identifying a sound as a cough. Agnosia can result from strokes, dementia, developmental disorders, or other neurological conditions. It typically results from damage to specific brain areas in the occipital or parietal lobes of the brain. People with agnosia may retain their cognitive abilities in other areas.

Wikipedia : 74 Agnosia is the inability to process sensory information. Often there is a loss of ability to recognize... more...

Related Diseases for Agnosia

Diseases in the Agnosia family:

Form Agnosia

Diseases related to Agnosia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 575)
# Related Disease Score Top Affiliating Genes
1 pain agnosia 33.4 TRPV1 TCF21 TAC1 RPL34 POMC PNOC
2 peripheral nervous system disease 31.5 TRPV1 TAC1 RPL34 POMC OPRM1 NPS
3 amnestic disorder 31.3 PDYN OPRM1 OPRK1 OPRD1 HTR3A CNR1
4 autism spectrum disorder 31.2 POMC OXT OPRM1 OPRL1 OPRK1 OPRD1
5 speech and communication disorders 31.1 TAC1 POMC OXT OPRM1
6 asperger syndrome 31.0 OXT OPRM1 CNR1
7 attention deficit-hyperactivity disorder 30.9 OXT OPRM1 ADRA2C ADRA2B ADRA2A
8 schizophrenia 30.9 POMC PDYN OXT OPRM1 HTR3A FAAH
9 autism 30.8 TAC1 POMC OXT OPRM1 HTR3A CNR1
10 withdrawal disorder 30.2 POMC PNOC PDYN OPRM1 OPRL1 OPRK1
11 anxiety 30.2 TAC1 POMC PNOC PDYN OXT OPRM1
12 alcohol dependence 30.1 POMC PNOC PDYN OXT OPRM1 OPRL1
13 ataxia, early-onset, with oculomotor apraxia and hypoalbuminemia 12.9
14 auditory agnosia 12.7
15 visual agnosia 12.7
16 ataxia-oculomotor apraxia 3 12.7
17 ataxia-oculomotor apraxia 4 12.7
18 rolandic epilepsy, mental retardation, and speech dyspraxia, x-linked 12.7
19 tactile agnosia 12.6
20 finger agnosia 12.6
21 verbal auditory agnosia 12.6
22 integrative agnosia 12.6
23 developmental dyspraxia 12.6
24 topographical agnosia 12.5
25 form agnosia 12.5
26 social emotional agnosia 12.5
27 apperceptive agnosia 12.5
28 associative agnosia 12.5
29 mirror agnosia 12.5
30 color agnosia 12.5
31 time agnosia 12.5
32 semantic agnosia 12.4
33 visual verbal agnosia 12.4
34 gait apraxia 12.4
35 spinocerebellar ataxia, autosomal recessive, with axonal neuropathy 2 12.3
36 apraxia of eyelid opening 12.3
37 primary progressive apraxia of speech 12.3
38 rolandic epilepsy-speech dyspraxia syndrome 12.2
39 autosomal recessive cerebellar ataxia-pyramidal signs-nystagmus-oculomotor apraxia syndrome 12.1
40 x-linked intellectual disability-ataxia-apraxia syndrome 12.1
41 astereognosia 12.0
42 pilarowski-bjornsson syndrome 11.9
43 poretti-boltshauser syndrome 11.9
44 childhood apraxia of speech 11.8
45 phonagnosia 11.7
46 autotopagnosia 11.7
47 birk-landau-perez syndrome 11.7
48 developmental coordination disorder 11.7
49 prosopagnosia 11.7
50 cortical deafness 11.7

Graphical network of the top 20 diseases related to Agnosia:



Diseases related to Agnosia

Symptoms & Phenotypes for Agnosia

UMLS symptoms related to Agnosia:


seizures, fever, dyspnea, edema, cachexia, vertigo, abnormality of extrapyramidal motor function, headache, torticollis, clumsiness, syncope, scanning speech, cyanosis, visual agnosia, icterus, signs and symptoms, signs and symptoms, digestive, other symbolic dysfunction, hot flushes, symptoms, muscle rigidity

MGI Mouse Phenotypes related to Agnosia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.25 ADRA2A ADRA2B ADRA2C CNR1 FAAH HTR3A
2 homeostasis/metabolism MP:0005376 10.16 ADRA2A ADRA2B ADRA2C CNR1 FAAH HTR3A
3 integument MP:0010771 10 CNR1 FAAH HTR3A OPRD1 OPRK1 OPRL1
4 nervous system MP:0003631 9.8 ADRA2A ADRA2C CNR1 FAAH HTR3A OPRD1
5 renal/urinary system MP:0005367 9.17 ADRA2B HTR3A OXT POMC TAC1 TCF21

Drugs & Therapeutics for Agnosia

Drugs for Agnosia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 128)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nalbuphine Approved Phase 4 20594-83-6 5311304 5360630
2
tannic acid Approved Phase 4 1401-55-4
3
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
4
Dezocine Approved, Investigational Phase 4 53648-55-8 40841 3033053
5
Flurbiprofen Approved, Investigational Phase 4 5104-49-4 3394
6
Cisatracurium Approved Phase 4 96946-41-7
7
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
8
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
9
Clonidine Approved Phase 4 4205-90-7 2803
10
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
11
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
12
Levobupivacaine Approved, Investigational Phase 4 27262-47-1 92253
13
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
14
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
15
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
16
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9 24083
17
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
18
Norepinephrine Approved Phase 4 51-41-2 439260
19
Codeine Approved, Illicit Phase 4 76-57-3 5284371
20
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
21
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
22
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
23
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
24
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
25
Butorphanol Approved, Illicit, Vet_approved Phase 4 58786-99-5, 42408-82-2 5361092
26
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
27
Morphine Approved, Investigational Phase 4 57-27-2 5288826
28
Acetaminophen Approved Phase 4 103-90-2 1983
29
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
30
Remifentanil Approved Phase 4 132875-61-7 60815
31
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
32
Ketoprofen Approved, Vet_approved Phase 4 22071-15-4 3825
33
Nefopam Approved, Investigational Phase 4 13669-70-0
34
Aspartic acid Approved, Nutraceutical Phase 4 56-84-8 5960
35
Butyric Acid Experimental, Investigational Phase 4 107-92-6 264
36 Neuromuscular Blocking Agents Phase 4
37 Tea Phase 4
38 Opiate Alkaloids Phase 4
39 Anticonvulsants Phase 4
40 HIV Protease Inhibitors Phase 4
41
protease inhibitors Phase 4
42 Dexamethasone 21-phosphate Phase 4
43 Sympatholytics Phase 4
44 Excitatory Amino Acid Antagonists Phase 4
45 N-Methylaspartate Phase 4
46 Anesthetics, Dissociative Phase 4
47 Anti-Anxiety Agents Phase 4
48 Psychotropic Drugs Phase 4
49 Sodium Channel Blockers Phase 4
50 Anti-Arrhythmia Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 202)
# Name Status NCT ID Phase Drugs
1 Ketamine and Postoperative Analgesia in Children Unknown status NCT00200564 Phase 4 ketamine
2 Intravenous Versus Caudal Supplementation of Ketamine for Postoperative Pain Control in Children,A Double-blind Controlled Clinical Trial. Unknown status NCT00532662 Phase 4 S(+)-ketamine
3 Postoperative Patient Controlled Epidural Analgesia After Total Knee Arthroplasty With 2ug/ml Fentanyl Combine With 0.2% Ropivacaine or 0.2% Levobupivcaine Unknown status NCT01158586 Phase 4 Levobupivacaine
4 Effect of Dexmedetomidine Combined With Dezocine and Flubiprofen for Postoperative Intravenous Patient Controlled Analgesia After Colorectal Surgery Unknown status NCT03014713 Phase 4 Dezocine;Flubiprofen;Dexmedetomidine
5 Analgesia After Total Knee Arthroplasty: Randomized Controlled Trial Comparing (a) Periarticular Multimodal Technique With (B) Continuous Femoral Nerve Block + Posterior Capsular Injection Unknown status NCT00869037 Phase 4 Periarticular Injection;CFNB + Posterior Capsular Injection
6 The Efficacy and Optimal Dose of Sufentanil in Patient Controlled Analgesia After Moderate Surgery Unknown status NCT02503826 Phase 4 Sufentanil;Sufentanil;Sufentanil;Midazolam;propofol;cisatracurium
7 Intraoperative and Postoperative Analgesia for Laparoscopic Surgery. Completed NCT00772187 Phase 4 morphine;intrathecal analgesia (morphine);general anesthesia (fentanyl)
8 Femoral Nerve Block Using 0.25% Versus 0.5% Bupivacaine for Analgesia After Arthroscopic Anterior Cruciate Ligament Reconstruction Completed NCT01593566 Phase 4 0.25% Bupivacaine;0.5% Bupivacaine
9 Analgesia Effects of Intravenous Ketamine After Spinal Anesthesia for Non-elective Cesarean Section Completed NCT03450499 Phase 4 Ketamine;Placebo
10 Multimodal Opiate-sparing Analgesia Versus Traditional Opiate Based Analgesia After Cardiac Surgery, a Randomized Controlled Trial Completed NCT01966172 Phase 4 Ibuprofen;Gabapentin;Morphine;Paracetamol
11 Intravenous Continuous Infusion of Dexamethasone Plus Tramadol Combined With Standard Morphine Patient-Controlled Analgesia After Total Abdominal Hysterectomy Completed NCT00564603 Phase 4 Dexamethasone Sodium Phosphate Injection
12 The Combination Effect of Dexmedetomidine and Morphine in Postoperative Patient-Controlled Analgesia Completed NCT00800826 Phase 4 dexmedetomidine
13 A Randomized Controlled Comparison of Different Dose Combinations of Bupivacaine and Sufentanil on Epidural Analgesia Onset Time and Adverse Reactions During Labor Completed NCT03395600 Phase 4 B1S5;B125S5;B1S10
14 Postoperative Pain and Systemic Inflammatory Stress Response (SIRS) After Preoperative Analgesia With Clonidine or Levobupivacaine Completed NCT00860899 Phase 4 clonidine, levobupivacaine
15 Levobupivacaine for Epidural Analgesia in Labour Completed NCT00929682 Phase 4 Randomization between two referenced treatments
16 Efficacy Of Scalp Block And Ultrasound Guided TAP Block With Clonidine As Adjuvant To Ropivacaine Versus Intravenous Fentanyl On Intraoperative Hemodynamics And Perioperative Analgesia In Abdominal Bone Flap Cranioplasties: A Prospective, Randomised, Double Blind Study Completed NCT03667352 Phase 4 Intravenous Fentanyl
17 Comparison of Intrathecal Morphine, Epidural Bupivacaine With Sufentanil and Systemic Patient Controlled Analgesia With Morphine for Analgesia After Colorectal Surgery: Prospective Randomised Study. Completed NCT03007121 Phase 4 Morphine intrathecal;Bupivacaine + Sufentanil epidural;Morphine intravenous
18 Effects of Catheter Location on Postoperative Analgesia for Continuous Adductor Canal and Popliteal-Sciatic Nerve Blocks Completed NCT02523235 Phase 4 ropivacaine 0.2%
19 Does Postoperative Administration of Oral Oxycodone With/Without Naloxone, Reduce the Duration of Epidural Analgesia in Patients Undergoing Cystectomy Without Impairing Its Benefits? A Randomized, Double Blind Controlled Trial Completed NCT02516059 Phase 4 oxycodone/naloxone;Oxycodone;Placebo
20 Longitudinal Multi-Modality Imaging in Progressive Apraxia of Speech Recruiting NCT01818661 Phase 4 AV-1451
21 Impact of Dexmedetomidine Supplemented Analgesia on 2-Year Survival in Elderly Patients After Cancer Surgery: a Multicenter Randomized Controlled Trial Recruiting NCT03012971 Phase 4 Dexmedetomidine supplemented morphine analgesia;Morphine analgesia
22 Evaluation of the Effect of Adding Magnesium Sulfate Infusion to Ketamine Infusion on Improvement of the Analgesic Efficacy in Cancer Breast Surgeries. Recruiting NCT04111848 Phase 4 Ketamine;ketamine and magnesium
23 Intravenous and Intraperitoneal Lignocaine for Perioperative Analgesia in Laparoscopic Colon Resections Recruiting NCT03105193 Phase 4 IV Saline bolus and infusion;IP Saline bolus and infusion;IV lignocaine bolus and infusion;IP Lignocaine bolus and infusion
24 Impact of Dexmedetomidine Supplemented Analgesia on Incidence of Delirium in Elderly Patients After Cancer Surgery: a Multicenter Randomized Controlled Trial Recruiting NCT03012984 Phase 4 Dexmedetomidine supplemented morphine analgesia;Morphine analgesia
25 Analgesic Efficacy of Ropivacaine Alone or in Combination With Adjuvants on Post-operative Analgesia Following Video-Assisted Thoracoscopic Surgery (VATS) - A Randomized Controlled Trial. Recruiting NCT03809442 Phase 4 Ropivacaine + Ketamine;Ropivacaine + Tramadol;Ropivacaine + Midazolam;Ropivacaine + Dexmedetomidine;Ropivacaine + Dexamethasone;Ropivacaine
26 Impact of Dexmedetomidine Supplemented Intravenous Analgesia on Postoperative Delirium and Long-term Outcomes in Elderly After Orthopedic Surgery: A Multicenter, Double-blinded, Randomized Controlled Trial Active, not recruiting NCT03629262 Phase 4 Dexmedetomidine;Placebo
27 Hydromorphone for ICU-analgesia in Patients With Non-mechanical Ventilation: A Dose-exploration and Effectiveness Study Not yet recruiting NCT04436224 Phase 4 Hydromorphone;Fentanyl;Butorphanol
28 Extension of the Analgesia of an Interscalene Block of the Brachial Plexus by Combined Injection of Dexamethasone and Dexmedetomidine, After Arthroscopic Shoulder Surgery: Randomized, Controlled, Double-blind Trial Not yet recruiting NCT04394481 Phase 4 Ropivacaine injection;Dexamethasone injection
29 Assessing the Impact of EXPAREL(R) on Opioid Use and Patient Reported Outcomes When Administered by Infiltration Into the Transversus Abdominis Plane (TAP) Under Ultrasound Guidance for Prolonged Postsurgical Analgesia in Lower Abdominal Surgeries Terminated NCT01919190 Phase 4 EXPAREL;Placebo
30 A Randomized, Open-label, Multicenter, Parallel-group Study to Compare the Efficacy, Safety and Resource Utilization of a Remifentanil/Propofol Analgesia/Sedation Regimen Versus a Sufentanil/Propofol Analgesia/Sedation Regimen in Mechanically Ventilated Intensive Care Patients Requiring Analgesia and Sedation for up to 7 Days Terminated NCT00421720 Phase 4 Sufentanil;Remifentanil
31 Prospective, Controlled Versus Placebo, Randomized, Double-blind Study, Evaluating the Value of Non-opioid Analgesic Combination (Based on Paracetamol, Nefopam, Ketoprofen) for Postoperative Analgesia. Terminated NCT01882530 Phase 4 Paracetamol;Nefopam;Ketoprofen;Morphine
32 The Effect of Pectoralis Block on Analgesia After Simple Mastectomy Withdrawn NCT03143530 Phase 4 Normal saline injection;Ropivacaine Injection
33 Laparoscopic Guided Transversus Abdominis Plane Block for Postoperative Analgesia After Pediatric Laparoscopic Surgery. Unknown status NCT03388671 Phase 2, Phase 3 Bupivacaine
34 COMBINATION OF CONTINUOUS FEMORAL BLOCK AND INTRAVENOUS PARECOXIB FOR POSTOPERATIVE ANALGESIA AFTER TOTAL KNEE ARTHROPLASTY. A DOUBLE BLIND PROSPECTIVE STUDY. Completed NCT02185924 Phase 2, Phase 3 Parecoxib;CONTINUOUS FEMORAL BLOCK WITH ROPIVACAINE 0,2%;N/S 0.9%
35 A Phase 3, Randomized, Double Blind, Saline Placebo and Active Controlled, Multicenter Study of HTX 011 Via Local Administration for Postoperative Analgesia and Decreased Opioid Use Following Unilateral Simple Bunionectomy Completed NCT03295721 Phase 3 HTX-011;Saline Placebo;Bupivacaine HCl
36 Is Continuous Wound Infusion With Ropivacaine Better Than Intrathecal Morphine for Post-caesarean Analgesia? A Prospective, Randomized, Controlled, Double Blinded Study Completed NCT02264821 Phase 3 ropivacaine infiltration;intrathecal morphine;placebo
37 Continuous Regional Analgesia After Total Knee Arthroplasty. Normal Saline or Dextrose 5% in Water as Fluid Medium for Pre-Placement Expansion in Order to Facilitate the Catheter Passing Completed NCT00337597 Phase 3
38 Post-Operatory Analgesia in Newborn Infants: a Comparative Study of Fentanyl Versus Tramadol Completed NCT00713726 Phase 3 FentanyL;Tramadol
39 A Phase 3, Randomized, Double Blind, Saline Placebo and Active Controlled, Multicenter Study of HTX 011 Via Local Administration for Postoperative Analgesia and Decreased Opioid Use Following Unilateral Open Inguinal Herniorrhaphy Completed NCT03237481 Phase 3 HTX-011;Bupivacaine HCl;Saline placebo
40 Epidural Analgesia During Labour Randomized Clinical Trial Comparing Patient Controlled Epidural Analgesia Versus Patient Intermittent Epidural Boluses With Levobupivacaine Completed NCT03133091 Phase 3 PIEB: Patient Intermittent Epidural Boluses;PCEA: Patient Controlled Epidural Analgesia
41 A PhaseⅡ/ Ⅲ Seamless Study to Evaluate Efficacy and Safety of Paracetamol Injection as Adjuvant to Morphine-based Postoperative Analgesia—Multicentered, Randomized, Double-blind, Placebo-controlled Clinical Trial Completed NCT02811991 Phase 2, Phase 3 Paracetamol injection;Normal Saline injection;Morhpine PCA
42 Evolution of Albumin on AOA1 Patients Supplemented With Coenzyme Q10 Completed NCT02333305 Phase 3
43 Analgesia for Neonatal Circumcision: A Randomized Controlled Clinical Trial of EMLA Versus Combination of EMLA, Sucrose and Dorsal Penile Nerve Block or Ring Block Completed NCT02990364 Phase 3 Sucrose;Lidocaine;EMLA Topical Product
44 A Non-Inferiority Randomized Trial Comparing the Impact of Thoracic Epidural Analgesia Versus Surgical Site Infiltration With Liposomal Bupivicaine on the Postoperative Recovery of Patients Following Open Gynecologic Surgery Not yet recruiting NCT04117074 Phase 3 Liposomal bupivacaine
45 Evaluation of the Analgesia by Serratus Plane Block During Pleural Drainage in Intensive Care Unit. Not yet recruiting NCT03984656 Phase 3 lidocaine treatment;serratus plane block treatment
46 A Randomized, Open Label, Multicentre Study to Compare the Pharmaco-economic Implications of an Analgesia Based Regimen With Remifentanil and a Conventional Sedation Based Regimen Using Propofol in Medical and Post-surgical ICU Subjects Requiring Mechanical Ventilation for at Least 2 Days. Terminated NCT00436345 Phase 3 Remifentanil;Propofol
47 Tramadol for Labor Analgesia in Low Risk Women: A Placebo Controlled Randomized Trial Unknown status NCT02999594 Phase 2 Tramadol Hydrochloride;Distilled Water
48 A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Four-Part Evaluation of the Efficacy and Safety of Locally Administered HTX-011 for Postoperative Analgesia Following Bunionectomy Completed NCT02471898 Phase 2 HTX-011;Placebo
49 A Phase 2, Randomized, Controlled Evaluation of the Efficacy and Safety of HTX-011 or HTX-002 for Post-Operative Analgesia Following Abdominoplasty Surgery Completed NCT02689258 Phase 2 HTX-011B;Placebo;HTX-011A;HTX-002;Bupivicaine HCl
50 A Phase 2b, Randomized, Double-Blind, Saline Placebo- and Active-Controlled, Multicenter Study of HTX-011 Via Infiltration for Postoperative Analgesia in Subjects Undergoing Total Knee Arthroplasty Completed NCT03015532 Phase 2 HTX-011;Saline Placebo;Bupivicaine HCl;Ropivacaine

Search NIH Clinical Center for Agnosia

Cochrane evidence based reviews: agnosia

Genetic Tests for Agnosia

Anatomical Context for Agnosia

MalaCards organs/tissues related to Agnosia:

40
Brain, Parietal Lobe, Cortex, Temporal Lobe, Testes, Breast, Eye

Publications for Agnosia

Articles related to Agnosia:

(show top 50) (show all 1480)
# Title Authors PMID Year
1
Cortical deafness of following bilateral temporal lobe stroke. 61
32386850 2020
2
Sexual Behavioral Disinhibition Associated with Nucleus Lentiformis Lesion: A Forensic Neuroscience Perspective Through a Case. 61
32525581 2020
3
Altered large-scale organization of shape processing in visual agnosia. 61
32574843 2020
4
'I see colors when I touch them'. Color agnosia with visuo-tactile facilitation in a patient with posterior cortical atrophy. 61
32171092 2020
5
Anton's Syndrome associated with autotopagnosia. 61
30661390 2020
6
Visual texture agnosia influences object identification in dementia with Lewy bodies and Alzheimer's disease. 61
32422422 2020
7
Music processing deficits in Landau-Kleffner syndrome: Four case studies in adulthood. 61
32442777 2020
8
Structural representations of fingers rely on both anatomical and spatial reference frames. 61
31985250 2020
9
Recovery from tactile agnosia: a single case study. 61
31755352 2020
10
Low Heteroplasmy Rates Argue Against the m.3243A>G Variant as the Cause of Auditory Agnosia. 61
31876652 2020
11
Auditory Agnosia for Environmental Sounds in Alzheimer's Disease: Not Hearing and Not Listening? 61
31958091 2020
12
Difficulty differentiating a case of posterior cortical atrophy from a psychogenic disturbance of vision. 61
30997705 2020
13
Vowel and Tone Identification for Mandarin Congenital Amusics: Effects of Vowel Type and Semantic Content. 61
31805240 2019
14
The neuropsychological rehabilitation of visual agnosia and Balint's syndrome. 61
29366371 2019
15
Looking beyond the face area: lesion network mapping of prosopagnosia. 61
31740940 2019
16
[Progressive supranuclear palsy-Richardson syndrome with visual attention disturbance (Holmes and Horrax) and ataxie optique (Garcin): a case report]. 61
31656263 2019
17
Avian agnosia: A window into auditory semantics. 61
31593713 2019
18
Central deafness: a review of past and current perspectives. 61
31066317 2019
19
Real-world size coding of solid objects, but not 2-D or 3-D images, in visual agnosia patients with bilateral ventral lesions. 61
30987739 2019
20
Mirror self recognition as a product of forward models; implications for delusions of body image and visual neglect. 61
31383321 2019
21
History of cerebral localization and the emigration plight of three neuroscience giants from Nazi Germany: Josef Gerstmann, Adolf Wallenberg, and Franz Josef Kallmann. 61
31473673 2019
22
Visual perceptual disorders in Alzheimer's disease. 61
31449049 2019
23
Proposal of situational-meaning agnosia/endogenous-reaction hypothesis for schizophrenia. 61
31269311 2019
24
Role of Population Receptive Field Size in Complex Visual Dysfunctions: A Posterior Cortical Atrophy Model. 61
31403655 2019
25
Prominent auditory deficits in primary progressive aphasia: A case study. 61
30878181 2019
26
The making of a syndrome: The English translation of Gerstmann's first report. 61
31029874 2019
27
Early prediction of long-term tactile object recognition performance after sensorimotor stroke. 61
30875614 2019
28
Atypical non-progressive semantic impairment following allogeneic bone marrow transplantation in a patient with Waldenström's macroglobulinemia: A case report. 61
30468103 2019
29
Late-onset Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like Episodes Presenting With Auditory Agnosia. 61
31045719 2019
30
Still holding after all these years: An action-perception dissociation in patient DF. 61
28951167 2019
31
Gray Matter Correlates of Finger Gnosis in Children: A VBM Study. 61
30699334 2019
32
Evidence of taxonomy for Developmental Topographical Disorientation: Developmental Landmark Agnosia Case 1. 61
29192795 2019
33
Functional connectivity and the failure to retrieve meaning from shape in visual object agnosia. 61
30591372 2019
34
Patient MW: transient visual hemi-agnosia. 61
30617908 2019
35
Evaluating object recognition ability in developmental prosopagnosia using the Cambridge Car Memory Test. 61
30973292 2019
36
Transient Dyschromatopsia, Static Form Agnosia, and Prosopagnosia Observed in a Patient with Anti-NMDA Receptor Encephalitis. 61
31061739 2019
37
An Uncommon Presentation of Mucopolysaccharidosis Type IIIb. 61
31327975 2019
38
Regression in children with epilepsy. 61
30537476 2019
39
Origin and evolution of human consciousness. 61
31703906 2019
40
Klüver-Bucy Syndrome Following Traumatic Brain Injury: A Systematic Synthesis and Review of Pharmacological Treatment From Cases in Adolescents and Adults. 61
30376788 2019
41
Hemineglect and Attentional Dysfunction. 61
31220845 2019
42
Differentiation of Types of Visual Agnosia Using EEG. 61
31735907 2018
43
Visual crowding in pure alexia and acquired prosopagnosia. 61
29902952 2018
44
The Visual Agnosias and Related Disorders. 61
28945627 2018
45
Topographical disorientation in aging. Familiarity with the environment does matter. 61
29948464 2018
46
PSEN1 p.Thr116Ile Variant in Two Korean Families with Young Onset Alzheimer's Disease. 61
30200536 2018
47
Neuromodulation of Right Auditory Cortex Selectively Increases Activation in Speech-Related Brain Areas in Brainstem Auditory Agnosia. 61
30239465 2018
48
Damasio's error - Prosopagnosia with intact within-category object recognition. 61
29845731 2018
49
The contribution of facial dynamics to subtle expression recognition in typical viewers and developmental visual agnosia. 61
29723598 2018
50
Body representation disorders predict left right orientation impairments after stroke: A voxel-based lesion symptom mapping study. 61
28732749 2018

Variations for Agnosia

Expression for Agnosia

Search GEO for disease gene expression data for Agnosia.

Pathways for Agnosia

Pathways related to Agnosia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.8 TAC1 POMC PNOC PDYN OXT OPRM1
2
Show member pathways
12.78 TRPV1 TAC1 POMC PNOC PDYN OXT
3
Show member pathways
12.2 OPRD1 ADRA2C ADRA2B ADRA2A
4
Show member pathways
11.93 POMC PDYN OPRM1 ADRA2C ADRA2B ADRA2A
5 11.67 POMC OPRM1 OPRD1
6
Show member pathways
11.59 ADRA2C ADRA2B ADRA2A
7
Show member pathways
11.49 ADRA2C ADRA2B ADRA2A
8 10.69 ADRA2C ADRA2B ADRA2A

GO Terms for Agnosia

Cellular components related to Agnosia according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 10.25 TYROBP TRPV1 TAC1 PNOC PDYN OPRM1
2 synapse GO:0045202 9.95 TRPV1 TAC1 PNOC OPRK1 HTR3A CNR1
3 integral component of plasma membrane GO:0005887 9.9 TYROBP TRPV1 OPRM1 OPRL1 OPRK1 OPRD1
4 dendrite GO:0030425 9.89 TRPV1 PNOC PDYN OPRM1 OPRK1
5 axon GO:0030424 9.85 TAC1 OPRM1 HTR3A CNR1 ADRA2C
6 neuron projection GO:0043005 9.85 TRPV1 OPRM1 OPRL1 OPRK1 OPRD1 HTR3A
7 neuronal cell body GO:0043025 9.8 TRPV1 TAC1 PNOC PDYN OPRK1 HTR3A
8 integral component of postsynaptic membrane GO:0099055 9.62 OPRM1 OPRK1 HTR3A ADRA2C
9 spine apparatus GO:0097444 9.43 OPRM1 OPRD1
10 axon terminus GO:0043679 9.35 PNOC PDYN OPRK1 OPRD1 ADRA2C
11 integral component of presynaptic membrane GO:0099056 9.02 OPRM1 OPRK1 OPRD1 HTR3A CNR1

Biological processes related to Agnosia according to GeneCards Suite gene sharing:

(show all 49)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.25 TYROBP POMC PNOC OXT OPRM1 OPRL1
2 chemical synaptic transmission GO:0007268 10.03 TAC1 PNOC PDYN OPRK1 HTR3A
3 cell-cell signaling GO:0007267 10.01 TAC1 POMC ADRA2C ADRA2B ADRA2A
4 response to ethanol GO:0045471 9.94 OPRM1 OPRK1 HTR3A CNR1
5 female pregnancy GO:0007565 9.9 PNOC OXT ADRA2C ADRA2B
6 positive regulation of MAPK cascade GO:0043410 9.88 ADRA2C ADRA2B ADRA2A
7 adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway GO:0007193 9.88 OPRM1 OPRL1 OPRK1 OPRD1 ADRA2A
8 glucose homeostasis GO:0042593 9.87 POMC CNR1 ADRA2A
9 platelet activation GO:0030168 9.87 ADRA2C ADRA2B ADRA2A
10 adenylate cyclase-modulating G protein-coupled receptor signaling pathway GO:0007188 9.86 CNR1 ADRA2C ADRA2B ADRA2A
11 cellular response to growth factor stimulus GO:0071363 9.85 TRPV1 OPRD1 HTR3A
12 regulation of insulin secretion GO:0050796 9.85 CNR1 ADRA2C ADRA2A
13 excitatory postsynaptic potential GO:0060079 9.85 TRPV1 OPRM1 HTR3A
14 response to cocaine GO:0042220 9.85 OXT OPRM1 OPRK1 HTR3A CNR1
15 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.84 OPRM1 OPRD1 CNR1
16 phospholipase C-activating G protein-coupled receptor signaling pathway GO:0007200 9.84 OPRM1 OPRK1 OPRD1
17 response to morphine GO:0043278 9.83 TAC1 OPRM1 OPRK1 CNR1
18 activation of protein kinase B activity GO:0032148 9.82 ADRA2C ADRA2B ADRA2A
19 negative regulation of blood pressure GO:0045776 9.81 OXT OPRL1 CNR1
20 sensory perception of pain GO:0019233 9.8 TRPV1 TAC1 OPRM1 OPRL1 OPRK1 CNR1
21 G protein-coupled receptor signaling pathway GO:0007186 9.8 TAC1 POMC PNOC PDYN OXT OPRM1
22 positive regulation of blood pressure GO:0045777 9.78 OXT CNR1 ADRA2B
23 regulation of vasoconstriction GO:0019229 9.77 ADRA2C ADRA2B ADRA2A
24 eating behavior GO:0042755 9.77 OXT OPRM1 OPRL1 OPRK1 OPRD1
25 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.76 ADRA2C ADRA2B ADRA2A
26 regulation of smooth muscle contraction GO:0006940 9.75 ADRA2C ADRA2B ADRA2A
27 estrous cycle GO:0044849 9.74 OPRM1 OPRL1 OPRK1
28 adrenergic receptor signaling pathway GO:0071875 9.72 ADRA2C ADRA2B ADRA2A
29 response to food GO:0032094 9.71 OXT OPRM1
30 negative regulation of norepinephrine secretion GO:0010700 9.71 ADRA2C ADRA2B ADRA2A
31 opioid receptor signaling pathway GO:0038003 9.71 OPRM1 OPRL1 OPRK1 OPRD1
32 response to pain GO:0048265 9.7 TRPV1 TAC1
33 positive regulation of ossification GO:0045778 9.69 TAC1 OXT
34 behavior GO:0007610 9.69 OPRL1 OPRK1
35 positive regulation of renal sodium excretion GO:0035815 9.69 TAC1 OXT
36 receptor transactivation GO:0035624 9.69 ADRA2C ADRA2B ADRA2A
37 maternal behavior GO:0042711 9.68 OXT OPRK1
38 positive regulation of synaptic transmission, GABAergic GO:0032230 9.68 TAC1 NPS
39 negative regulation of heart rate GO:0010459 9.68 TRPV1 TAC1
40 negative regulation of epinephrine secretion GO:0032811 9.67 ADRA2C ADRA2B ADRA2A
41 positive regulation of uterine smooth muscle contraction GO:0070474 9.66 OXT ADRA2B
42 negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway GO:0106072 9.65 OPRM1 OPRL1
43 positive regulation of action potential GO:0045760 9.65 TAC1 NPS
44 sensory perception GO:0007600 9.65 PNOC PDYN OPRM1 OPRL1 OPRK1
45 conditioned place preference GO:1990708 9.63 OPRL1 OPRK1
46 regulation of sensory perception of pain GO:0051930 9.63 OXT OPRM1 OPRL1 OPRK1 OPRD1 ADRA2C
47 positive regulation of gastric acid secretion GO:0060454 9.62 TRPV1 OPRL1
48 adenylate cyclase-inhibiting opioid receptor signaling pathway GO:0031635 9.62 OPRM1 OPRK1
49 neuropeptide signaling pathway GO:0007218 9.28 TAC1 POMC PNOC PDYN OPRM1 OPRL1

Molecular functions related to Agnosia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.92 OPRM1 OPRL1 OPRK1 OPRD1 CNR1 ADRA2C
2 peptide binding GO:0042277 9.67 OPRM1 OPRL1 OPRK1 OPRD1
3 adrenergic receptor activity GO:0004935 9.58 ADRA2C ADRA2B ADRA2A
4 receptor serine/threonine kinase binding GO:0033612 9.48 OPRK1 OPRD1
5 opioid receptor binding GO:0031628 9.46 PNOC PDYN
6 neuropeptide binding GO:0042923 9.46 OPRM1 OPRL1 OPRK1 OPRD1
7 opioid peptide activity GO:0001515 9.43 PNOC PDYN
8 epinephrine binding GO:0051379 9.43 ADRA2C ADRA2B ADRA2A
9 alpha2-adrenergic receptor activity GO:0004938 9.13 ADRA2C ADRA2B ADRA2A
10 opioid receptor activity GO:0004985 8.92 OPRM1 OPRL1 OPRK1 OPRD1

Sources for Agnosia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....